Merck’s targeted chemotherapy sac-TMT posted additional phase 3 momentum from China, with sac-TMT plus Keytruda delaying tumor progression versus chemotherapy plus Keytruda in first-line PDL1-negative, non-squamous lung cancer. Analysts framed the OptiTROP-Lung05 results as a direct proof of concept for sac-TMT’s role in future standard therapy. The OptiTROP-Lung05 readout marks a second China-run superiority study for sac-TMT in lung cancer, adding weight to Merck’s positioning of sac-TMT as a cornerstone option that could reshape combinations in the EGFR/PD-(L)1-adjacent treatment landscape where front-line choice can be pivotal. For investors and clinicians, the key implication is not just efficacy—it's the reinforcement of a specific, repeatable benefit signal across China-led phase 3 programs.